this issue:
Safety and efficacy of high-dose biotin in progressive MS
Five years of ocrelizumab in relapsing MS
Inner retinal layer thinning in RIS predicts conversion to MS
AHSCT vs alemtuzumab for relapsing-remitting MS
Effectiveness of different natalizumab interval dosing schedules for MS
Delay from treatment start to full effect of immunotherapies for MS
DMTs can reduce disability progression in relapsing MS
Change in MS prevalence over time in Australia 2010-2017
OCT measures correlate with brain and spinal cord atrophy and MS disease-related disability
Pathological correlates of MTR in MS
Please login below to download this issue (PDF)